Skip to main content
University of California San Francisco
UCSF Health
Search UCSF
About UCSF
Precision Medicine at UCSF
Search form
Search...
About
UCSF Precision Medicine Platform Committee
Office of Science Policy and Strategy
Staff
Diversity, Equity, and Inclusion
The Elements of Precision Medicine
Basic Discovery
Building The Knowledge Network
Clinical Discovery
Computational Health Sciences
Digital Health
Ethics and Engagement
Imaging
'Omics Medicine
Population Sciences
Programs
Precision Cancer Medicine
Precision Population Health
Women's Precision Medicine
Children's Precision Medicine
Precision Medicine Access and Value Program
Projects
News & Events
Scientific Publications
Newsletter
Events
Resources
UCSF Centers & Affiliates
Funding Opportunities
You are here
Home
>
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Filter Scientific Publications
By Date
By Date
Date
E.g., 04-24
By Date
Date
E.g., 04-24
Scientific Area
Artificial Intelligence (AI)
Basic Science
Clinical
Computational Science
COVID-19
Data
Digital Health
Equity
Ethics
General - Precision Medicine
Genomics
Imaging
Immunology
Microbiome
Omics
Oncology
Pediatrics
Pharmacogenomics
Population & Public Health
Quality Improvement
Sequencing
Social & Behavioral
